Ceconomic Observer Network Over the past 7 days (February 5 to 11, 2026), Wanchun Medicine (BYSI.OQ) experienced significant stock price fluctuations, with a total decline of 7.01% and a volatility of 9.55%. The stock price movement was mainly influenced by low market liquidity (daily trading volume consistently below $51,000). No major event announcements or industry hot topics directly related to the company were found within the past 7 days. The latest data shows that as of February 11, 2026, the company’s total market capitalization is approximately $60 million, with a trailing twelve months price-to-earnings ratio (TTM) of negative (-146), indicating weak fundamentals (the 2025 fiscal year quarterly report shows zero revenue and ongoing net losses).
The above content is compiled from publicly available information and does not constitute investment advice.
View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Wanchun Pharmaceutical stock price has decreased by 7% in the past week, with a market capitalization of approximately $60 million.
Ceconomic Observer Network Over the past 7 days (February 5 to 11, 2026), Wanchun Medicine (BYSI.OQ) experienced significant stock price fluctuations, with a total decline of 7.01% and a volatility of 9.55%. The stock price movement was mainly influenced by low market liquidity (daily trading volume consistently below $51,000). No major event announcements or industry hot topics directly related to the company were found within the past 7 days. The latest data shows that as of February 11, 2026, the company’s total market capitalization is approximately $60 million, with a trailing twelve months price-to-earnings ratio (TTM) of negative (-146), indicating weak fundamentals (the 2025 fiscal year quarterly report shows zero revenue and ongoing net losses).
The above content is compiled from publicly available information and does not constitute investment advice.